Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more
Nanobiotix (NBTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.253x
Based on the latest financial reports, Nanobiotix (NBTX) has a cash flow conversion efficiency ratio of 0.253x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.41 Million) by net assets ($-68.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nanobiotix - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Nanobiotix's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nanobiotix Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanobiotix ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DEVELIA S.A. INH. ZY 1
F:94L
|
N/A |
|
GRUPO ELEKTRA (GE7C.SG)
STU:GE7C
|
0.204x |
|
Ganzhou Tengyuan Cobalt New Material Co. Ltd.
SHE:301219
|
N/A |
|
China Southern Power Grid Energy Efficiency & Clean Energy Co Ltd
SHE:003035
|
0.087x |
|
Corvus Pharmaceuticals Inc
NASDAQ:CRVS
|
-0.133x |
|
Trupanion Inc
NASDAQ:TRUP
|
0.076x |
|
Khang Dien House Trading and Investment JSC
VN:KDH
|
0.006x |
|
The First Bancshares, Inc.
NASDAQ:FBMS
|
0.018x |
Annual Cash Flow Conversion Efficiency for Nanobiotix (2011–2024)
The table below shows the annual cash flow conversion efficiency of Nanobiotix from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-65.70 Million | $-19.55 Million | 0.298x | -95.60% |
| 2023-12-31 | $-1.84 Million | $-12.48 Million | 6.766x | +393.15% |
| 2022-12-31 | $-27.05 Million | $-37.10 Million | 1.372x | +223.04% |
| 2021-12-31 | $26.79 Million | $-29.87 Million | -1.115x | -185.33% |
| 2020-12-31 | $70.47 Million | $-27.54 Million | -0.391x | -101.81% |
| 2019-12-31 | $-1.91 Million | $-41.17 Million | 21.566x | +1282.07% |
| 2018-12-31 | $14.24 Million | $-25.98 Million | -1.824x | -280.98% |
| 2017-12-31 | $43.92 Million | $-21.03 Million | -0.479x | +54.43% |
| 2016-12-31 | $17.40 Million | $-18.28 Million | -1.051x | +2.47% |
| 2015-12-31 | $15.61 Million | $-16.82 Million | -1.077x | -281.37% |
| 2014-12-31 | $30.32 Million | $-8.56 Million | -0.283x | +86.84% |
| 2013-12-31 | $3.18 Million | $-6.83 Million | -2.147x | -506.57% |
| 2012-12-31 | $10.70 Million | $-3.79 Million | -0.354x | +93.28% |
| 2011-12-31 | $925.53K | $-4.87 Million | -5.265x | -- |